(1) Nature and the quantity of the products to be
procured:
A Aflibercept (Genetical Recombination)
40 mg/mL set of 1 vial: approx. 1087 sets
B Lenalidomide Hydrate 5 mg set of
40 capsules: approx. 270 sets
C Nivolumab (Genetical Recombination) 240 mg
set of 1 vial: approx. 170 sets
D Ranibizumab (Genetical Recombination) Kit
10 mg/mL set of 1 kit: approx. 369 sets
E Daratumumab (Genetical Recombination)
400 mg set of 1 vial: approx. 293 sets
F Pembrolizumab (Genetical Recombination)
100 mg/4mL set of 1 vial: approx. 224 sets
G Golimumab (Genetical Recombination) 50 mg
Syringe set of 1 syringe: approx. 454 sets
H Palivizumab (Genetical Recombination)
100 mg set of 1 vial: approx. 288 sets
I Infliximab (Genetical Recombination)
100 mg set of 1 vial: approx. 518 sets
J Durvalumab (Genetical Recombination)
120 mg/2.4mL set of 1 vial: approx. 321 sets
(2) Time limit for tender: 17:00 on September 10
(Thu.), 2020
(3) Contact point for the notice:
Management & Planning Section, Management
Department, Management Office, Hospital
Bureau, Sapporo Municipal Government, Kita 11-
jo Nishi 13-chome, Chuo-ku, Sapporo 060-8604,
Japan.